PharmaSGP Holding presented half-year figures for 2020 today. Across the group, the company achieved an increase in sales from EUR 31.6 million to EUR 33.8 million. Before interest and taxes, the newcomer to the stock exchange reported a profit of 10.6 million euros after 9 million euros in the same period last year. Unadjusted, a profit of 9.5 million euros before interest and taxes was achieved, so the PharmaSGP Holding.
“We are extremely satisfied with our strong corporate development in the first half of 2020. We have very successfully further developed the product portfolio through line extensions, the development of new indication areas and the further expansion of international markets. With a total of seven launches, we even exceeded the originally planned number of new products in the first half of the year, ”says Natalie Weigand, CEO of PharmaSGP.
On a full-year basis, the company aims to increase the growth rate in the first half of 2020 and also increase the EBIT margin for the first half of the year.